There is a significant issue with current treatments for peripheral artery disease (PAD) using stents.
From preventing blood clots or reducing infection, to minimising painful fibrosis associated with implants, BIOINVISIBLE offers a more sustainable and recovery-driven solution to patients and industry.
It is anti-thrombogenic, anti-proliferative and evidence also now demonstrates extreme reduction in biofilm.
Download our BIOINVISIBLE brochure & read more
Get the leading medical device coating technology that prevents the build-up of platelets, proteins and cells.
BIOINVISIBLE is a highly biocompatible coating that helps to make implantable materials less ‘visible’ to the body’s normal immune defences.
Currently, medical device complications result in implant failure rates of up to 30%, leaving many patients requiring additional medical intervention and surgery causing significant discomfort, morbidity or even death.
BIOINVISIBLE™ is the solution to reducing this failure rate.
Several studies have shown that opportunistic pathogenic yeast C. albicans can form polymicrobial biofilms, in vitro and in vivo, and that these biofilms can affect disease course and management. Polymicrobial biofilms such as this are often resistant to antimicrobial drugs.
Many researchers have tried to target microbial biofilms to reduce their impact on patient outcomes, however unfortunately current conventional antimicrobial strategies don’t work well to counter biofilm development.
Platelets can play a key role in initiating the clotting cascade, through their adhesion and activation on the surface of implanted materials.
As a very hydrophilic coating, BIOINVISIBLE™ acts as a physical barrier on devices, markedly reducing adhesion of proteins, cells and other blood components onto biomaterials.
It’s dramatic effect on platelet adhesion onto coated stainless steel can be seen in the images. This can reduce the likelihood of a clot forming on the surface.
Upon adhesion and activation, platelets on the surface of a device will release a series of chemicals that initiate the clotting cascade. This results in the formation of an insoluble fibrin mesh that further attracts other platelets, proteins and cells, driving the formation of a blood clot.
The images show the insoluble fibrin protein extending from the activated platelets across the surface of the uncoated woven polymer strands. In contrast, by reducing the adhesion of platelets, BIOINVISIBLE™ coated strands showed no signs of a fibrin mesh.
For a patient receiving a stent, the formation of fibrin clots on the surface of the stent can lead to a catastrophic blood clot that will occlude the vessel and require emergency surgical intervention.
The ability of BIOINVISIBLE™ to create a barrier on the surface of stents, means blood flows normally over the stent surface, reducing platelet adhesion and the formation of a blood clot, as in the images to the right.
TekCyte’s unique coating has the potential to not only reduce complications from vascular devices, but it may also reduce the need for long-term anti-coagulant therapy for many patients requiring these devices.
We use a patented process where devices are coated with BIOINVISIBLE, a hydrophilic hyperbranched polyglycerol (HPG) polymer. This process allows the polymer to form directly from the surface of devices without the need for solvents.
Devices coated with BIOINVISIBLE repel platelets that can cause blood clots and potentially life-threatening complications for patients.
BIOINVISIBLE is easily applied to a wide range of metallic and polymer-based materials used in medical devices.
Vascular stents coated with BIOINVISIBLE repel platelets. This prevents blood clots which can lead to potential life-threatening complications for patients.
The BIOINVISIBLE process has patents granted in the US, Europe, China, Japan and Australia.
Platelets are implicated in the development of stent thrombosis and in-stent restenosis. For a patient receiving a stent, the formation of fibrin clots on the surface of the stent can lead to larger and life-threatening blood clots that can block arteries, requiring emergency surgical intervention.
TekCyte’s BIOINVISIBLE coating creates a barrier on the surface of stents, which means the blood can flow normally over the stent surface. This reduces platelet adhesion and activation, greatly reducing the likelihood of a blood clot.
The unique coating has the potential to not only reduce complications from vascular devices, but it may also reduce the need for long-term anti-coagulant therapy for many patients requiring these devices.
Mouse models of restenosis show that BIOINVISIBLE coated stents significantly reduce the level of in-stent restenosis, compared with uncoated stents.
TekCyte is a world leader in the development and manufacture of advanced coatings for medical devices and biomedical applications.
Company: Tekcyte
Address: Level 3, Material and Minerals (MM) Building, UniSA Mawson Lakes Campus, Mawson Lakes, SA, 5095, Australia
Phone: +61 8 8302 3491
Email: info@tekcyte.com
Select your desired option below to share a direct link to this page.
Your friends or family will thank you later.
